Taguchi, Kazuaki

写真a

Affiliation

Faculty of Pharmacy, Department of Pharmacy 薬効解析学講座 (Shiba-Kyoritsu)

Position

Associate Professor
Page Top ▲

Career 【 Display / hide 】

  • 2010.04
    -
    2011.03

    日本学術振興会特別研究員

  • 2011.04
    -
    2013.03

    熊本大学医学部附属病院, 薬剤部, 薬剤師

  • 2013.04
    -
    2017.03

    崇城大学　, 薬学部, 助教

  • 2018.04
    -
    2021.03

    慶應義塾大学, 薬学部, 専任講師

  • 2021.04
    -
    Present

    慶應義塾大学, 薬学部, 准教授

Page Top ▲

Academic Background 【 Display / hide 】

  • 2006.03

    Kumamoto University, 薬学部

    University, Graduated

  • 2008.03

    Kumamoto University

    Graduate School, Completed, Master's course

  • 2011.03

    Kumamoto University

    Graduate School, Completed, Doctoral course

Page Top ▲

Academic Degrees 【 Display / hide 】

  • 博士 (薬学), 熊本大学, 2011.03

Page Top ▲

Licenses and Qualifications 【 Display / hide 】

  • 薬剤師, 2006.04

Page Top ▲
 

Books 【 Display / hide 】

  • Carbon monoxide-bound Hemoglobin-Vesicles: Current facts and potential medical applications.

    Taguchi K, Matsumoto K, Sakai H, Maruyama T, Otagiri M, World Scientific Publishing Co. Pte. Ltd., 2021.12

    Scope: Chapter 6.10.,  Contact page： 849-865

  • ＤＤＳ先端技術の製剤への応用開発

    宗慶太郎, 田口和明, 技術情報協会, 2017

    Scope: 第6章6節 pp. 360-8

  • Human Serum Albumin (HSA): Functional Structure, Synthesis and Therapeutic Uses

    Taguchi K, Chuang VT, Yamasaki K, Otagiri M., Nova Science Publishers, Inc., 2015

    Scope: Chapter 4, pp. 69-89

  • HUMAN SERUM ALBUMIN

    Taguchi K, Chuang VT, Otagiri M., 2013

    Scope: Chapter 20, pp. 401-15

  • Acute Phase Proteins

    Taguchi K, Nishi K, Chuang VT, Maruyama T, Otagiri M., Intech, 2013

    Scope: Chapter 6, pp.139-62

Page Top ▲

Papers 【 Display / hide 】

  • Investigating the hypothermic effects of fluoroquinolone antimicrobials on non-bacterial fever model mice

    Hara R., Taguchi K., Ogino H., Okamoto Y., Enoki Y., Kizu J., Hori S., Matsumoto K.

    Journal of Pharmaceutical Health Care and Sciences 10 ( 1 ) 68 2024.12

    ISSN  2055-0294

    　View Summary

    Background: Fluoroquinolone (FQ) antimicrobials have antipyretic effects during the treatment of bacterial infections; however, it is not clear whether these are due to their antimicrobial activities or their hypothermic effects. In this study, we investigated the hypothermic effects of FQ antimicrobials (ciprofloxacin [CPFX], gatifloxacin [GFLX], and levofloxacin [LVFX]) on fever by evaluating rectal body temperature changes in a mouse model of non-bacterial fever. Methods: CPFX, GFLX, and LVFX were administered intraperitoneally to non-bacterial fever model mice induced by yeast. Rectal body temperature was measured up to 180 min after administration. Results: A decrease in rectal body temperature of up to 1.2 °C for CPFX, 3.4 °C for GFLX, and 1.0 °C for LVFX was observed. The decrease in temperature was induced by an increase in the plasma concentration of FQ antimicrobials, suggesting that they are responsible for the temperature reduction. Focusing on glucocorticoids, one thermoregulation mechanism, we investigated the substances responsible for the reduction in rectal body temperature induced by FQ antimicrobials. Aminoglutethimide (an inhibitor of glucocorticoid production) were premedicated, followed by intraperitoneal administration of GFLX in the yeast-induced fever mouse model, resulting in attenuated GFLX-induced hypothermic effects. Conclusions: These results suggest that certain antipyretic effects of CPFX, GFPX, and LVFX during fever may contribute to their hypothermic effects; certain mechanisms are glucocorticoid-mediated.

  • Development of a pharmacokinetic/pharmacodynamic evaluation model for osteomyelitis and usefulness of tedizolid as an alternative to vancomycin against MRSA osteomyelitis.

    Liu X, Enoki Y, Taguchi K, Matsumoto K

    The Journal of pharmacy and pharmacology  2024.11

    ISSN  0022-3573

  • Hydrosulphide-methaemoglobin-albumin cluster: a hydrogen sulphide donor

    Suzuki Y., Yamada T., Enoki Y., Matsumoto K., Komatsu T., Taguchi K.

    Journal of Materials Chemistry B 12 ( 44 ) 11515 - 11522 2024.10

    ISSN  2050750X

    　View Summary

    Methaemoglobin (metHb) possesses inherent characteristics that facilitate reversible binding to hydrogen sulphide. Exogenous hydrogen sulphide supplementation imparts beneficial bioactive effects, including antioxidant and anti-inflammatory; hence, we hypothesized that the metHb-hydrogen sulphide complex could act as a hydrogen sulphide donor for medication. In this study, we prepared a hydrosulphide-metHb-albumin (H2S-metHb-albumin) cluster and examined its applicability as a hydrogen sulphide donor in the mice model of hepatic ischemia-reperfusion injury. Structural analysis revealed that the H2S-metHb-albumin cluster exhibited a nanostructure wherein one metHb was wrapped by an average of three albumins, and hydrogen sulphide was bound to the haem. Additionally, the H2S-metHb-albumin cluster exhibited low-pH responsiveness, leading to sustained release of hydrogen sulphide. Owing to these structural and pharmaceutical characteristics, the severity of hepatic ischemia-reperfusion injury was alleviated via antioxidant and anti-inflammatory effects of the H2S-metHb-albumin cluster treatment. The protective effects were more potent in the H2S-metHb-albumin cluster compared to that in a conventional hydrogen sulphide donor (sodium hydrogen sulphide). No abnormal signs of toxic and biological responses were observed after the H2S-metHb-albumin cluster administration, confirming high biological compatibility. These results successfully establish the proof of concept that the H2S-metHb-albumin cluster is a promising hydrogen sulphide donor. To the best of our knowledge, this is the first report demonstrating the remarkable potential of metHb as a biomaterial for hydrogen sulphide donors.

  • Carbon monoxide-loaded red blood cells ameliorate metabolic dysfunction-associated steatohepatitis progression via enhancing AMP-activated protein kinase activity and inhibiting Kupffer cell activation

    Yanagisawa H., Maeda H., Noguchi I., Tanaka M., Wada N., Nagasaki T., Kobayashi K., Kanazawa G., Taguchi K., Chuang V.T.G., Sakai H., Nakashima H., Kinoshita M., Kitagishi H., Iwakiri Y., Sasaki Y., Tanaka Y., Otagiri M., Watanabe H., Maruyama T.

    Redox Biology 76   103314 2024.10

    ISSN  22132317

    　View Summary

    Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive form of nonalcoholic fatty liver disease characterised by fat accumulation, inflammation, oxidative stress, fibrosis, and impaired liver regeneration. In this study, we found that heme oxygenase-1 (HO-1) is induced in both MASH patients and in a MASH mouse model. Further, hepatic carbon monoxide (CO) levels in MASH model mice were >2-fold higher than in healthy mice, suggesting that liver HO-1 is activated as MASH progresses. Based on these findings, we used CO-loaded red blood cells (CO-RBCs) as a CO donor in the liver, and evaluated their therapeutic effect in methionine-choline deficient diet (MCDD)-induced and high-fat-diet (HFD)-induced MASH model mice. Intravenously administered CO-RBCs effectively delivered CO to the MASH liver, where they prevented fat accumulation by promoting fatty acid oxidation via AMP-activated protein kinase (AMPK) activation and peroxisome proliferator-activated receptor induction. They also markedly suppressed Kupffer cell activation and their corresponding anti-inflammatory and antioxidative stress activities in MASH mice. CO-RBCs also helped to restore liver regeneration in mice with HFD-induced MASH by activating AMPK. We confirmed the underlying mechanisms by performing in vitro experiments in RAW264.7 cells and palmitate-stimulated HepG2 cells. Taken together, CO-RBCs show potential as a promising cellular treatment for MASH.

  • Antimicrobial Stewardship of Oral Third-Generation Cephalosporins in Community Pharmacy: A Single-Center Quasi-Experimental Study

    Nakamura K., Matsumoto K., Enoki Y., Taguchi K., Yamashita S., Kai J., Hayashi H.

    Biological and Pharmaceutical Bulletin 47 ( 8 ) 1447 - 1451 2024.08

    ISSN  09186158

    　View Summary

    Proper use of antimicrobials in hospital and outpatient settings is critical for minimizing the occurrence of antimicrobial resistance. Some hospitals have intervened in the inappropriate use of third-generation oral cephalosporins. However, there have been no such studies in community pharmacy settings. This study aimed to investigate how the use of oral third-generation cephalosporins in community pharmacies affects the amount of antimicrobials used. Patients who visited Nakanomaru Pharmacy after being prescribed antimicrobials at target medical institutions between February 2021 and January 2023 were identified. The number of oral antimicrobials used, duration of use, number of prescriptions, patient age and sex, and infectious diseases in the target patients before and after the intervention for the proper use of oral third-generation cephalosporins were retrospectively investigated based on the patients’ medication history and prescription receipts. Through efforts to ensure the proper use of oral third-generation cephalosporins, the amount of oral third-generation cephalosporins used has decreased, and the use of penicillins and oral first-generation cephalosporins has increased. There was no increase in the antimicrobial change or relapse rates associated with treatment failure before and after the initiation of appropriate antimicrobial use. By working toward the proper use of oral third-generation cephalosporins in community pharmacies, we were able to reduce the doses of oral third-generation cephalosporins without compromising their therapeutic efficacy. We believe that recommending the selection of narrow-spectrum antimicrobials based on these guidelines will contribute to their proper use.

display all >>

Page Top ▲

Papers, etc., Registered in KOARA 【 Display / hide 】

Page Top ▲

Reviews, Commentaries, etc. 【 Display / hide 】

  • The charm of protein for drug development

    Ishima Y., Taguchi K.

    Yakugaku Zasshi (Yakugaku Zasshi)  140 ( 2 ) 139 - 140 2020.02

    ISSN  00316903

  • 細胞型人工赤血球の動態特性解析に基づく安全性評価と医療ガスデリバリーへの応用

    田口 和明

    YAKUGAKU ZASSHI 138   1381 - 1389 2018

    Article, review, commentary, editorial, etc. (scientific journal), Single Work

  • Comparison of the pharmacokinetic properties of hemoglobin-based oxygen carriers.

    Taguchi K, Yamasaki K, Maruyama T, Otagiri M.

    J Funct Biomater. 8 ( 1 ) E11 2017

    Article, review, commentary, editorial, etc. (scientific journal), Joint Work

  • The use of Hemoglobin vesicles for delivering medicinal gas for the treatment of intractable disorders.

    Taguchi K, Yamasaki K, Sakai H, Maruyama T, Otagiri M.

    J Pharm Sci. 106 ( 9 ) 2392 - 2400 2017

    Article, review, commentary, editorial, etc. (scientific journal), Joint Work

  • TDMの落とし穴～偽陽性と偽陰性～.

    田口和明, 猿渡淳二, 平田憲史郎, 丸山徹.

    医療薬学 41 ( 4 ) 215 - 222 2015

    Article, review, commentary, editorial, etc. (scientific journal), Joint Work

display all >>

Page Top ▲

Presentations 【 Display / hide 】

  • 良質な薬物治療を目指したアカデミア創薬・育薬研究

    田口和明

    日本薬学会第144年会, 

    2024.03
    , 

    Symposium, workshop panel (nominated)

  • ヘモグロビン小胞体投与が薬物動態関連タンパク質に与える影響

    田口和明、酒井宏水、松元一明、小田切優樹

    第30回 日本血液代替物学会 年次大会, 

    2023.12
    , 

    Symposium, workshop panel (nominated)

  • セルフメディケーション税制に対する理解度と意識の実態調査

    田口和明

    医療経済研究会, 

    2023.07
    , 

    Public lecture, seminar, tutorial, course, or other speech

  • 一酸化炭素結合型ヘモグロビン小胞体の薬剤誘発性臓器傷害に対する抑制効果

    田口和明、酒井宏水、小田切優樹、松元一明

    第29回日本血液代替物学会, 

    2022.12
    , 

    Symposium, workshop panel (nominated)

  • 長期備蓄を目指した凍結乾燥粉末化メトヘモグロビン-アルブミンクラスター

    田口和明、鈴木悠斗、岡本航、小松晃之、松元一明

    第29回日本血液代替物学会, 

    2022.12
    , 

    Symposium, workshop panel (nominated)

display all >>

Page Top ▲

Research Projects of Competitive Funds, etc. 【 Display / hide 】

  • ヘモグロビンを基盤とした次世代型高感度ナノMRI造影剤の開発

    2022.06
    -
    2025.03

    MEXT,JSPS, Grant-in-Aid for Scientific Research, 挑戦的研究（萌芽）, Principal investigator

  • サイトカインストーム制圧を目指したマクロファージ標的化一酸化炭素ナノ供与体の創製

    2022.04
    -
    2026.03

    MEXT,JSPS, Grant-in-Aid for Scientific Research, 基盤研究(B), Principal investigator

  • ヘモグロビン内封リポソームを用いたシアン化物中毒解毒剤の開発

    2019.04
    -
    2021.03

    橋渡し研究戦略的推進プログラム　シーズA, Other, Principal investigator

  • 震災特有疾患に対する一酸化炭素結合型ヘモグロビン小胞体の医薬品としての有用性評価

    2017.04
    -
    2020.03

    MEXT,JSPS, Grant-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (C), Principal investigator

  • 一酸化炭素結合ヘモグロビン小胞体の多機能型蘇生剤としての有用性評価

    2014.04
    -
    2017.03

    科学研究費補助金・若手研究B, Research grant, Principal investigator

display all >>

Page Top ▲

Intellectual Property Rights, etc. 【 Display / hide 】

  • メトヘモグロビン小胞体を有効成分として含む医薬およびその使用

    Date applied： 特願2020-144044,PCT/JP2021/ 31458  2020.08 

    Patent, Joint

  • 横紋筋融解症治療剤

    Date issued： 特許第6523842号  2019.05

    Patent, Joint

Page Top ▲

Awards 【 Display / hide 】

  • 熊本大学学長賞

    2011.03

  • 日本薬学会九州支部学術奨励賞

    2017.12

  • 日本薬学会奨励賞

    2020.03

    Type of Award： Award from Japanese society, conference, symposium, etc.

  • 日本DDS学会奨励賞 (臨床)

    2021.06, 日本DDS学会

    Type of Award： Award from Japanese society, conference, symposium, etc.

  • 日本薬物動態学会奨励賞

    2021.11, 日本薬物動態学会

    Type of Award： International academic award (Japan or overseas)

Page Top ▲
 

Courses Taught 【 Display / hide 】

  • STUDY OF MAJOR FIELD (PHARMACODYNAMICS)

    2024

  • SEMINAR (PHARMACODYNAMICS)

    2024

  • RESEARCH FOR BACHELOR'S THESIS 1

    2024

  • PRIOR LEARNING FOR CLINICAL PRACTICE 1

    2024

  • PRE-CLINICAL TRAINING FOR HOSPITAL & COMMUNITY PHARMACY

    2024

display all >>

Page Top ▲